Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat (SAHA) in Recurrent Glioblastoma
NCT00238303Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2005
- Primary completion
- Jul 2008
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vorinostat in glioblastoma multiforme (GBM) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Proportion of Successes (Patients Alive and Progression-free) at 6 months and Safety and Toxicity. Started Sep 2005; status: completed.
02
Drugs
vorinostat
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00238303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238303.